Exhibit 99.1
MATERIAL CHANGE REPORT
Regulation 51-102 Respecting Continuous Disclosure Obligations
Form 51-102F3
ITEM 1 - NAME AND ADDRESS OF COMPANY
THERATECHNOLOGIES INC.
2310 Alfred-Nobel Boulevard
Montreal, Québec
Canada H4S 2B4
ITEM 2 - DATE OF MATERIAL CHANGE
December 3, 2013
ITEM 3 - NEWS RELEASE
A news release describing this material change was issued on December 3, 2013 on “Marketwire”. A copy of the news release is available on the SEDAR website at www.sedar.com.
ITEM 4 - SUMMARY OF MATERIAL CHANGE
On December 3, 2013, Theratechnologies Inc. (the “Corporation”) announced that it resumed shipment ofEGRIFTATM (tesamorelin for injection) to EMD Serono, Inc. in the United States.
The Corporation also announced that it was notified by Jubilant HollisterStier (“Jubilant”), its third-party contract manufacturer of tesamorelin, that the strike initiated by Jubilant’s employees at its manufacturing site located in Montreal, Canada, was over.
ITEM 5 - FULL DESCRIPTION OF MATERIAL CHANGE
5.1 Full description of material change
On December 3, 2013, the Corporation announced that it resumed shipment ofEGRIFTATM (tesamorelin for injection) to EMD Serono, Inc. in the United States.
The Corporation also announced that it was notified by Jubilant, its third-party contract manufacturer of tesamorelin, that the strike initiated by Jubilant’s employees at its manufacturing site located in Montreal, Canada, was over.
5.2 Disclosure for restructuring transactions
Not applicable.
- 2 -
ITEM 6 - RELIANCE ON SUBSECTION 7.1(2) OR (3) OF NATIONAL INSTRUMENT 51-102
Not applicable.
ITEM 7 - OMITTED INFORMATION
Not applicable.
ITEM 8 - EXECUTIVE OFFICER
For further information, contact Jocelyn Lafond, Vice President, Legal Affairs, and Corporate Secretary of the Corporation at (514) 336-4804, ext. 288.
ITEM 9 - DATE OF REPORT
December 9, 2013.